Sign in
4

Changes in Ownership

CRISPR Therapeutics AG Filed Acc 0001209191-22-060387

Chief Executive Officer acquired 58,233 shares (option exercise)

From the SEC's structured data for this filing

Trades in this filing

Insider Date Transaction Shares Price Value Owned after D/I In the form
Kulkarni Samarth Chief Executive Officer 2022-12-06 Option exercise +58,233 $1.81 $105,402 369,111 D
Derivatives
Kulkarni Samarth Chief Executive Officer 2022-12-06 Option exercise · Stock Option (Right to Buy) −58,233 0 D
Loading xslF345X03/doc4.xml…